These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33626233)

  • 1. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
    Zhang D; Reyes RM; Osta E; Kari S; Gupta HB; Padron AS; Kornepati AVR; Kancharla A; Sun X; Deng Y; Wu B; Vadlamudi R; Li R; Svatek RS; Curiel TJ
    Cancer Med; 2021 Mar; 10(6):2137-2152. PubMed ID: 33626233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
    Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Clark CA; Gupta HB; Sareddy G; Pandeswara S; Lao S; Yuan B; Drerup JM; Padron A; Conejo-Garcia J; Murthy K; Liu Y; Turk MJ; Thedieck K; Hurez V; Li R; Vadlamudi R; Curiel TJ
    Cancer Res; 2016 Dec; 76(23):6964-6974. PubMed ID: 27671674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.
    Svatek RS; Ji N; de Leon E; Mukherjee NZ; Kabra A; Hurez V; Nicolas M; Michalek JE; Javors M; Wheeler K; Sharp ZD; Livi CB; Shu ZJ; Henkes D; Curiel TJ
    Cancer Immunol Res; 2019 Mar; 7(3):466-475. PubMed ID: 30563829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer.
    Tsai TF; Chang AC; Chen PC; Ho CY; Chen HE; Chou KY; Hwang TI
    J Cell Physiol; 2022 Sep; 237(9):3587-3597. PubMed ID: 35903922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer.
    Zhang J; Zhou Q; Xie K; Cheng L; Peng S; Xie R; Liu L; Zhang Y; Dong W; Han J; Huang M; Chen Y; Lin T; Huang J; Chen X
    J Exp Clin Cancer Res; 2021 Jun; 40(1):203. PubMed ID: 34154613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
    Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
    Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential.
    Clark CA; Gupta HB; Curiel TJ
    Autophagy; 2017 May; 13(5):987-988. PubMed ID: 28368722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.
    Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2019 Aug; 38(35):6270-6282. PubMed ID: 31316145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
    Hu W; Ma Y; Zhao C; Yin S; Hu H
    Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells.
    Sciarretta F; Fulci C; Palumbo C; Rotili D; Tentori L; Graziani G; Caccuri AM
    Chemotherapy; 2019; 64(3):138-145. PubMed ID: 31639786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
    Wang Y; Zhang M; Wang Z; Guo W; Yang D
    Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.
    Song L; Liu S; Zhao S
    Bioengineered; 2022 Apr; 13(4):11240-11257. PubMed ID: 35485300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
    Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
    Mani J; Vallo S; Rakel S; Antonietti P; Gessler F; Blaheta R; Bartsch G; Michaelis M; Cinatl J; Haferkamp A; Kögel D
    BMC Cancer; 2015 Apr; 15():224. PubMed ID: 25885284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.
    Cao D; Qi Z; Pang Y; Li H; Xie H; Wu J; Huang Y; Zhu Y; Shen Y; Zhu Y; Dai B; Hu X; Ye D; Wang Z
    Cancer Res; 2019 May; 79(10):2604-2618. PubMed ID: 30808674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.